Current status of adjuvant endocrine therapy for breast cancer

Clinical Cancer Research

Volumn 7, Issue , 2001, Pages 4392s-4396s

  Ingle, James N ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ESTROGEN RECEPTOR; EXEMESTANE; FLUOROURACIL; GONADORELIN DERIVATIVE; LETROZOLE; PROGESTERONE RECEPTOR; TAMOXIFEN;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RECURRENCE; CLINICAL TRIAL; CONFERENCE PAPER; FEMALE; HORMONE SENSITIVITY; HUMAN; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; RECURRENCE RISK; TREATMENT INDICATION;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CLINICAL TRIALS; CONSENSUS DEVELOPMENT CONFERENCES, NIH; FEMALE; HORMONES; HUMANS; MENOPAUSE; NEOADJUVANT THERAPY; RECEPTORS, ESTROGEN; UNITED STATES;

EID: 0035668672     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Menopause and breast cancer risk
2. Tamoxifen in the treatment of breast cancer
3. Tamoxifen for early breast cancer: An overview of the randomised trials
4. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: Updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial
5. Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre- and postmenopausal breast cancer patients
6. In situ aromatization enhances breast tumor estradiol levels and cellular proliferation
7. Superior efficacy of letrozole (Femara) versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group
8. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial
9. Anastrazole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study
10. Preliminary results of two multicenter trials comparing the efficacy and tolerability of Arimidex (anastrozole) and tamoxifen (TAM) in post menopausal (PM) women with advanced breast cancer (ABC)
11. Aromatase inhibition and antiestrogen therapy in early breast cancer treatment and chemoprevention
12. Ovarian ablation in early breast cancer: Overview of the randomised trials
13. Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: The Scottish trial
14. Treatment with a luteinising-hormone-releasing-hormone analogue (buserelin) in premenopausal patients with metastatic breast cancer
15. An individual patient-based meta-analysis of tamoxifen versus ovarian ablation as first line endocrine therapy for premenopausal women with metastatic breast cancer
16. A multi-center randomized clinical trial of goserelin versus surgical ovariectomy in pre-menopausal patients with receptor positive metastatic breast cancer: An intergroup study
17. Zoladex (goserelin) vs. CMF as adjuvant therapy in pre-/perimenopausal early (node positive) breast cancer: Preliminary efficacy. QOL and BMD results from the ZEBRA study
18. Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: A randomized study
19. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: A meta-analysis of four randomized trials
20. Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: Results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial
21. Comparison of adjuvant therapy with tamoxifen and goserelin vs. CMF in premenopausal stage I and II hormone-responsive breast cancer patients: Four-year results of Austrian Breast Cancer Study Group (ABCSG) Trial 5
22. Combination goserelin and tamoxifen is more effective than CMF in premenopausal patients with hormone-responsive tumors in a multicenter trial of the Austrian Breast Cancer Study Group (ABCSG)
23. Effect of chemohormonal therapy in premenopausal, node (+), receptor (+) breast cancer: An Eastern Cooperative Oncology Group phase III intergroup trial (E5188, Int-0101)
24. Castration and tamoxifen versus chemotherapy (FAC) for premenopausal, node and receptors positive breast cancer patients: A randomized thai with a 7 years median follow up
25. Complete hormonal, blockade versus chemotherapy in premenopausal early-stage breast cancer patients (Pts) with positive hormone-receptor (HT+) and 1-3 node-positive (N+) tumor: Results of the FASG 06 trial
26. Polychemotherapy for early breast cancer: An overview of the randomised trials
27. Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: Results of The International Breast Cancer Study Group (IBCSG) Trial IV
28. Randomized trial to evaluate the addition of tamoxifen to cyclophosphamide, 5-fluorouracil, prednisone adjuvant therapy in premenopausal women with node-positive breast cancer
29. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer
30. Rate of chemotherapy related amenorrhea (CRA) associated with adjuvant Adriamycin and Cytoxan (AC) and Adriamycin and Cytoxan followed by Taxol (AC+T) in early stage breast cancer
31. Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?
32. National Institutes of Health Consensus Development Conference Statement: Adjuvant therapy for breast cancer; November 1-3, 2000